Analysis of changes in plasma cytokine levels in response to interleukin 12 therapy in three clinical trials.

ABSTRACT: The ability of interleukin 12 (IL-12) to stimulate NK and T cell anti-tumor activity makes it an attractive candidate for the immune therapy of cancer. Our group has demonstrated that IL-12 enhances NK cell responses to antibody-coated tumor cells and conducted three clinical trials utilizing IL-12 with monoclonal antibodies (OSU-9968, OSU-0167 and OSU-11010). To better characterize IL-12-induced immunity, plasma cytokine levels were measured in 21 patients from these trials with favorable and unfavorable responses. t-statistics and linear modeling were used to test for differences within and between response groups by examining levels at baseline and post-IL-12 administration. Patients exhibited significant increases in eleven cytokines post-IL-12 administration when analyzed collectively

SUBMITTER: Schwarz E 

PROVIDER: S-EPMC10777814 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature